Información de Regenxbio Inc, dividendo de Regenxbio Inc, actividades de los accionistas y más

Más Datos de Regenxbio Inc Compañía

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Información de Regenxbio Inc



Símbolo de cotizaciónRGNX

Nombre de la empresaRegenxbio Inc

Fecha de salida a bolsaSep 17, 2015

Director ejecutivoMr. Curran M. Simpson

Número de empleados353

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 17

Dirección9804 Medical Center Drive

CiudadROCKVILLE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal20850

Teléfono12405528181

Sitio Webhttps://regenxbio.com/

Símbolo de cotizaciónRGNX

Fecha de salida a bolsaSep 17, 2015

Director ejecutivoMr. Curran M. Simpson

Ejecutivos de Regenxbio Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

16.11K

-48.81%

Mr. Allan M. Fox, J.D.

Director

--

Dr. David C. (Dave) Stump, M.D.

Independent Director

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: sáb., 8 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Otro

64.66%

Accionistas

Proporción

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Otro

64.66%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

33.94%

Investment Advisor

31.21%

Hedge Fund

12.74%

Individual Investor

7.62%

Research Firm

6.92%

Pension Fund

0.28%

Bank and Trust

0.26%

Family Office

0.26%

Private Equity

0.06%

Otro

6.73%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

403

44.05M

87.32%

-5.71M

2025Q2

421

48.19M

95.62%

-3.63M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Redmile Group, LLC

4.78M

9.45%

-19.06K

-0.40%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.27M

8.45%

+348.80K

+8.90%

Jun 30, 2025

The Vanguard Group, Inc.

3.42M

6.77%

-51.80K

-1.49%

Jun 30, 2025

Fox (Allan Mark)

2.90M

5.74%

+7.77K

+0.27%

May 30, 2025

JP Morgan Asset Management

2.99M

5.91%

+38.82K

+1.32%

Jun 30, 2025

State Street Investment Management (US)

1.84M

3.65%

+777.55K

+72.93%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.73M

3.43%

+637.97K

+58.36%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.61M

3.18%

+962.62K

+149.64%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.13M

2.23%

+21.57K

+1.95%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

1.12M

2.22%

-24.96K

-2.17%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

WisdomTree BioRevolution Fund

1.92%

iShares Neuroscience and Healthcare ETF

0.79%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Global X Genomics & Biotechnology ETF

0.51%

JPMorgan Fundamental Data Science Small Core ETF

0.32%

ALPS Medical Breakthroughs ETF

0.29%

SPDR S&P Biotech ETF

0.16%

Direxion Daily S&P Biotech Bull 3X Shares

0.09%

iShares Health Innovation Active ETF

0.09%

Fidelity Enhanced Small Cap ETF

0.08%

WisdomTree BioRevolution Fund

Proporción1.92%

iShares Neuroscience and Healthcare ETF

Proporción0.79%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.68%

Global X Genomics & Biotechnology ETF

Proporción0.51%

JPMorgan Fundamental Data Science Small Core ETF

Proporción0.32%

ALPS Medical Breakthroughs ETF

Proporción0.29%

SPDR S&P Biotech ETF

Proporción0.16%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.09%

iShares Health Innovation Active ETF

Proporción0.09%

Fidelity Enhanced Small Cap ETF

Proporción0.08%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos